Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01760304 · ClinicalTrials.gov registry record · Phase 4
Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT01760304 is a Phase 4 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 5 participants.
The verdict
NCT01760304, a Phase 4 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
To investigate whether Budesonide/Formoterol (Symbicort ®) therapy can improve heart function at rest by decreasing lung hyperinflation in patients with COPD (Chronic Obstructive Pulmonary Disease).
Interventions
- DRUG Placebo
- DRUG Budesonide / Formoterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01760304
The ClinicalTrials.gov registry entry for NCT01760304 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01760304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01760304 about?
NCT01760304 is a clinical study titled "Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo". To investigate whether Budesonide/Formoterol (Symbicort ®) therapy can improve heart function at rest by decreasing lung hyperinflation in patients with COPD (Chronic Obstructive Pulmonary Disease).
What is the current status of trial NCT01760304?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2012-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01760304?
The interventions under investigation include: Placebo (DRUG), Budesonide / Formoterol (DRUG).
Who is sponsoring clinical trial NCT01760304?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.